Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) is anticipated to announce its Q4 2026 resultson Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors can check the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Tuesday, September 22, 2026 at 4:00 PM ET.
Anebulo Pharmaceuticals Stock Performance
Anebulo Pharmaceuticals stock opened at $0.30 on Monday. The firm has a market capitalization of $12.24 million, a price-to-earnings ratio of -1.58 and a beta of -1.82. The firm’s fifty day moving average price is $0.32 and its two-hundred day moving average price is $0.45. Anebulo Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $2.85.
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc (NASDAQ: ANEB) is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and other conditions associated with cannabinoid use. The company’s work is aimed at addressing medical needs for patients experiencing severe or potentially dangerous effects from cannabis and related substances.
Anebulo’s lead product candidate, ANEB-001, is an orally administered small-molecule antagonist of the cannabinoid 1 (CB1) receptor.
Featured Articles
- Five stocks we like better than Anebulo Pharmaceuticals
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
- These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
